1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > LARGE CAP PHARMA US & EU OUTLOOK 2016: MAXIMIZING THEIR STRENGTH ON FEWER THERAPY CLASS, PERSONALIZED MEDICINE, NOVEL TARGET AND BIOSIMILARS FOR FUTURE GROWTH

LARGE CAP PHARMA US & EU OUTLOOK 2016: MAXIMIZING THEIR STRENGTH ON FEWER THERAPY CLASS, PERSONALIZED MEDICINE, NOVEL TARGET AND BIOSIMILARS FOR FUTURE GROWTH

  • March 2016
  • -
  • MP Advisors
  • -
  • 97 pages

Summary

Table of Contents

Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, vaccines and consumer health care business. Oncology segment has been the key areas of interest for large cap Pharma companies in 2014/2015. The field of immuno-oncology is currently one of the most explosive fields in biotechnology.

Bristol-Myers’s with more concentrated effort in Immuno-Oncology has gain the leadership with its Anti-PD-1 drug. Along with Bristol, there's Merck (MRK), Roche (RHHBY), and AstraZeneca (AZN) as well chasing the field. The global estimates of Immuno-oncology drug is expected at >$40 billion in next ten years. Anti-Infective remains a big attraction for large pharm. Merck acquisition of Cubist for $9 billion and Roche’ in-licensing deal for $1billion was the key highlight. Biosimilar development from Large ad Biotech companies are progressing well with many reaching to regulatory space and in lates stage of clinical trials. Biogen Idec streamlined its focus to develop drugs for specialty medicine (Multiple Sclerosis, Inflammatory Bowel Disease), Neurodegeneration (Alzheimer’s disease, Parkinson’s, ALS, Neuro-immunology) and rare diseases (Hemophilia, Spinal Muscular Atrophy and Neuropathic Pain).

Celgene (CELG) keeps capitalizing on its strength in hematology and operational excellence to build global standards of care in the segments of Oncology and Inflammation & Immunology (I&I). Gilead, a prominent player in Hepatitis C therapy areas is looking to expand its learning in Liver disease for another high unmet need of Nonalcoholic Steatohepatitis (NASH), while its Oncolgy segment failed to make any major impact other than approved drug Zydelig. First – in-class mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors continue to get attraction by large cap pharma companies. Biotech and pharmaceutical companies pursue targeted and specialized therapies – more than 25% (45 new drugs approval vs. 44 in 2014) of drugs approved by FDA in 2015 are Personalized Medicines.

Global Biopharmaceutical Outlook 2016-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2017 World Transfusion Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Transfusion Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 43500
  • Industry report
  • January 2017
  • by Venture Planning Group

This comprehensive 68-country report from VPGMarketResearch.com provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market ...

2017 World Blood Typing, Grouping and Infectious Disease Screening Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Blood Typing, Grouping and Infectious Disease Screening Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 43500
  • Industry report
  • January 2017
  • by Venture Planning Group

This comprehensive 68-country report from VPGMarketResearch.com provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market ...


Download Unlimited Documents from Trusted Public Sources

Mental Health Statistics in the US

  • April 2017
    6 pages
  • Mental Health  

  • United States  

View report >

Endocrine Disease Statistics in the US

  • April 2017
    122 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Mental Health Statistics in the US - Forecast

  • April 2017
    3 pages
  • Mental Health  

    Neurological Di...  

  • United States  

View report >

Obesity Statistics

8 days ago

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.